Epithalon (Epitalon) · Research brief

Epithalon Mechanism of Action Detailed | Real Peptides

Real Peptides Research TeamEditorial

Updated April 7, 202611 min read

54 WORDS

Short answer

Most anti-aging interventions target downstream symptoms. Oxidative damage, inflammation, cellular debris accumulation. Epithalon works upstream, at the chromosomal level, by reactivating telomerase in differentiated somatic cells that otherwise lack meaningful enzyme expression after embryonic development. This isn't incremental damage mitigation. It's architectural restoration of the cellular aging clock itself. Research conducted at the St.

Key takeaways

Epithalon activates telomerase reverse transcriptase (TERT) in somatic cells, enabling enzymatic elongation of telomeres that standard cellular machinery cannot extend. A 1.6 kilobase mean increase was observed in human lymphocytes after six months.
The peptide upregulates pineal melatonin synthesis by 1.8–2.3-fold in aged models, restoring circadian amplitude that declines 50–80% with aging and contributes to oxidative stress and immune dysfunction.
Epithalon modulates core circadian clock genes ( CLOCK , BMAL1 , PER1 , CRY1 ), influencing metabolic and immune function through neuroendocrine pathways independent of telomere length.
In rodent longevity studies, Epithalon extended median lifespan by 12–16% and reduced spontaneous tumor incidence, though human lifespan data do not exist. Current evidence is limited to biomarker changes and healthspan proxies.
The peptide reduces lipid peroxidation, increases endogenous antioxidant enzyme activity (SOD, catalase, glutathione peroxidase), and inhibits NF-κB inflammatory signaling in multiple tissue types.
Unlike metabolic interventions (metformin, resveratrol) or mTOR inhibitors (rapamycin), Epithalon directly targets chromosomal maintenance. Making it a distinct tool for studying replicative senescence versus other aging mechanisms.

Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology demonstrated that Epithalon administration increased mean telomere length in human peripheral blood lymphocytes by 1.6–1.8 kilobases after six months. A finding that doesn't align with passive antioxidant mechanisms or simple metabolic modulation. The peptide initiates active enzymatic extension of chromosomal end-caps that standard cellular machinery considers permanently shortened.

What is Epithalon's mechanism of action at the cellular level?

Epithalon (Ala-Glu-Asp-Gly) activates telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase enzyme, in somatic cells where the gene is normally silenced post-development. This reactivation allows elongation of telomeric DNA repeats (TTAGGG sequences) that otherwise shorten with each cell division. Simultaneously, the peptide upregulates pineal melatonin synthesis and modulates circadian gene expression. Creating multi-system effects beyond chromosomal maintenance alone.

The Featured Snippet answer covers what Epithalon does. What it doesn't cover is why this matters for research into aging biology. Telomere shortening triggers the Hayflick limit. The point at which cells enter permanent growth arrest (senescence) after approximately 50–70 divisions. Reactivating telomerase in adult tissue theoretically delays or reverses this countdown, but the body silences TERT expression in most differentiated cells precisely because unrestricted telomerase activity is characteristic of 85–95% of human cancers. Epithalon's mechanism sits at the intersection of regenerative potential and oncogenic risk. And understanding that trade-off is the core of its research value. This article covers the specific biochemical pathways Epithalon engages, how those mechanisms differ from other longevity compounds, and what the evidence from controlled studies actually demonstrates about functional outcomes.

Telomerase Activation and Chromosomal Maintenance

Telomeres are protective nucleotide caps (5–15 kilobases in humans) at chromosome ends that prevent DNA degradation and fusion events during replication. Each mitotic division shortens telomeres by 50–200 base pairs due to the end-replication problem. DNA polymerase cannot fully replicate the 3' lagging strand terminus. Once telomeres reach a critical threshold (typically 4–6 kilobases), the cell activates p53 and p21 pathways that halt division permanently.

Telomerase reverse transcriptase (TERT) is the enzyme that synthesizes new TTAGGG repeats onto telomeric ends using its integral RNA template (TERC). In humans, TERT is highly expressed in germ cells, stem cells, and activated lymphocytes. But transcriptionally silenced in most somatic tissue after embryonic development. This silencing is an evolutionary tumor-suppression mechanism: without a mitotic clock, cells with oncogenic mutations could replicate indefinitely.

Epithalon demonstrates dose-dependent upregulation of TERT mRNA and protein expression in cultured human fibroblasts, with peak activity observed at 10–50 µM concentrations in vitro. The peptide does not directly bind telomerase. Instead, it modulates transcription factors upstream of the TERT promoter region, including c-Myc and Sp1, both known positive regulators of telomerase gene expression. Research published in Bulletin of Experimental Biology and Medicine found Epithalon increased telomerase activity in peripheral blood mononuclear cells by 33–42% relative to baseline within 10 days of subcutaneous administration at 10 mg per cycle.

The functional consequence is measurable telomere elongation. A controlled human study involving elderly participants (mean age 72 years) showed 1.6 kilobase mean increase in lymphocyte telomere length after two 10-day courses of Epithalon separated by six months. Importantly, this elongation occurred without detectable increase in circulating tumor markers or abnormal cell proliferation. Suggesting the activation remains within physiological regulatory bounds, at least over the study's 12-month observation window.

For researchers examining cellular senescence, Epithalon offers a tool to test whether telomere restoration alone is sufficient to delay replicative aging or whether telomere length is merely a biomarker rather than a driver. Our work with laboratories sourcing Epithalon Peptide consistently highlights this distinction: the peptide doesn't prevent all forms of cellular aging. Oxidative damage, mitochondrial dysfunction, and epigenetic drift continue. But it does remove one specific constraint on proliferative capacity.

Pineal Gland Modulation and Circadian Regulation

The second major pathway through which Epithalon's mechanism of action operates is direct modulation of pineal gland function. The pineal gland synthesizes melatonin, the primary hormonal regulator of circadian rhythm, from serotonin via the rate-limiting enzyme aralkylamine N-acetyltransferase (AANAT). Melatonin secretion follows a pronounced circadian pattern. Low during daylight, peaking 2–4 hours after darkness onset. And this rhythm deteriorates with age. Elderly individuals show 50–80% reduced nocturnal melatonin amplitude compared to young adults, correlating with sleep fragmentation, desynchronized cortisol patterns, and increased oxidative stress.

Epithalon administration restores age-related declines in melatonin synthesis. Studies in aged rats demonstrated 1.8–2.3-fold increases in nocturnal pineal melatonin content after 10-day Epithalon treatment cycles, with effects persisting 30–60 days post-administration. The mechanism involves upregulation of AANAT gene expression and enzymatic activity, likely mediated through Epithalon's influence on pineal peptide signaling networks that regulate transcription factor binding at the AANAT promoter.

Melatonin itself exerts pleiotropic effects: direct free-radical scavenging (melatonin neutralizes hydroxyl radicals, peroxynitrite, and singlet oxygen), mitochondrial membrane stabilization, and modulation of autophagy pathways through AMPK and mTOR signaling. Restoration of physiological melatonin rhythm therefore contributes to Epithalon's broader anti-aging profile independent of telomerase activation.

Additionally, Epithalon influences expression of core circadian clock genes including CLOCK, BMAL1, PER1, and CRY1 in peripheral tissues. Circadian disruption accelerates metabolic dysfunction, immune senescence, and cancer risk. Re-establishing robust oscillatory gene expression may underlie some of Epithalon's systemic health effects observed in long-term rodent studies, including extended median lifespan (12–16% in multiple strains), reduced spontaneous tumor incidence, and preservation of immune function.

For research programs examining chronobiology or neuroendocrine aging, Epithalon serves as a pharmacological probe to dissect melatonin-dependent versus melatonin-independent longevity pathways. Researchers studying related neuroendocrine peptides often compare outcomes with compounds like Pinealon, which targets CNS function through distinct receptor-mediated pathways.

Antioxidant, Neuroprotective, and Immunomodulatory Mechanisms

Beyond telomerase and pineal modulation, Epithalon mechanism of action detailed includes secondary antioxidant and neuroprotective pathways. The tetrapeptide reduces lipid peroxidation markers (malondialdehyde, 4-hydroxynonenal) and increases activity of endogenous antioxidant enzymes. Superoxide dismutase (SOD), catalase, and glutathione peroxidase. In multiple tissue types. In cultured neurons exposed to oxidative stress (hydrogen peroxide or amyloid-beta), Epithalon pretreatment (1–10 µM) reduced apoptotic cell death by 35–50% and preserved mitochondrial membrane potential.

The neuroprotective effect extends to in vivo models. Aged rats receiving Epithalon demonstrated improved spatial memory retention in Morris water maze testing, correlated with reduced hippocampal neuronal loss and lower levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in brain tissue homogenates. The anti-inflammatory mechanism likely involves NF-κB pathway inhibition, as Epithalon reduces nuclear translocation of the p65 subunit in activated microglia.

Immunomodulation represents another facet. Epithalon increases thymic weight and cellularity in aged animals, enhances proliferative response of T-lymphocytes to mitogens (concanavalin A, phytohemagglutinin), and shifts cytokine profiles toward Th1-dominant patterns associated with effective pathogen clearance. This immune restoration mirrors findings with thymic peptides such as Thymalin, though Epithalon's effect appears mediated through both direct thymic tissue interaction and indirect neuroendocrine signaling via the hypothalamic-pituitary-thymus axis.

Critically, these mechanisms do not operate in isolation. Telomerase activation influences mitochondrial function independently of telomere length. TERT localizes to mitochondria under oxidative stress and reduces reactive oxygen species production. Melatonin upregulation enhances DNA repair capacity through SIRT1 activation. The net result is a multi-system intervention where individual pathways reinforce one another, complicating mechanistic attribution but potentially explaining Epithalon's broad phenotypic effects in longevity studies.

Epithalon Mechanism of Action Detailed: Pathway Comparison

Understanding how Epithalon's mechanism of action differs from alternative longevity interventions clarifies its research utility and limitations.

Intervention	Primary Mechanism	Telomerase Activation	Melatonin Modulation	Evidence Tier	Bottom Line
Epithalon	TERT upregulation, pineal restoration, circadian gene expression	Direct (33–42% increase in PBMC activity)	Direct (1.8–2.3× nocturnal synthesis in aged models)	Controlled human trials (small N), extensive rodent data	Multi-pathway intervention with chromosomal and neuroendocrine targets. Strongest evidence for telomere elongation in somatic cells
TA-65 (Astragalus extract)	Alleged telomerase activation via cycloastragenol	Weak (minimal activity in published assays, no consistent telomere lengthening)	None	Observational studies only, no RCTs	Marketed as telomerase activator but mechanistic evidence is inconclusive; effects likely antioxidant rather than enzymatic
Resveratrol	SIRT1 activation, mitochondrial biogenesis, AMPK pathway	Indirect (SIRT1 may influence TERT transcription weakly)	Indirect (phase-shifts circadian clock genes)	Extensive preclinical data, human RCTs show minimal longevity biomarker changes	Metabolic modulator with disputed translation to humans; does not directly target telomeres
Metformin	AMPK activation, mTOR inhibition, mitochondrial complex I modulation	None	None	Large epidemiological datasets, ongoing RCTs (TAME trial)	Caloric restriction mimetic with systemic metabolic effects; no chromosomal maintenance mechanism
NAD+ precursors (NMN, NR)	NAD+ repletion, SIRT enzyme cofactor availability	Indirect (SIRT1/6 may influence TERT promoter activity)	None	Human trials show NAD+ increases but limited functional outcome data	Targets age-related NAD+ decline; overlaps with Epithalon via SIRT pathways but distinct primary mechanism
Rapamycin	mTOR inhibition, autophagy induction, immune modulation	None	None	Robust lifespan extension in multiple model organisms, human trials for specific indications	Strongest preclinical longevity data but no telomere mechanism; immunosuppressive at higher doses

Epithalon occupies a unique position as one of the few compounds with direct evidence for somatic telomerase activation in humans. This distinguishes it from metabolic or epigenetic interventions that may improve healthspan without addressing replicative senescence. However, the long-term safety profile in humans remains less characterized than metformin or rapamycin, both repurposed from clinical use with decades of pharmacovigilance data.

What If: Epithalon Research Scenarios

What If Telomerase Activation Increases Cancer Risk in Long-Term Use?

Limit exposure duration to intermittent cycles rather than continuous administration. The cancer concern is mechanistically valid. 85–95% of malignancies upregulate telomerase to achieve replicative immortality. But short-term activation in non-transformed cells has not produced detectable tumor formation in controlled studies. A 10-day cycle every 6–12 months mimics the protocol used in human trials showing telomere elongation without malignancy markers over 12 months. Continuous high-dose exposure has not been evaluated in humans and would represent uncharted oncogenic territory.

What If Epithalon's Effects Are Primarily Melatonin-Mediated Rather Than Telomere-Dependent?

Compare outcomes with exogenous melatonin supplementation at equivalent circadian restoration doses. If Epithalon's lifespan or healthspan benefits in rodents are fully replicated by melatonin alone (typically 1–10 mg/kg depending on species and administration route), the telomerase mechanism may be biomarker-relevant but not functionally causal for longevity. Published data suggest partial overlap. Melatonin extends lifespan modestly in some strains but does not lengthen telomeres. Indicating the mechanisms are complementary rather than redundant.

What If Human Translation Fails Despite Robust Rodent Data?

Prioritize biomarker validation over lifespan endpoints. Telomere length, telomerase activity, and melatonin rhythm are directly measurable in humans within months, whereas lifespan requires decades. If Epithalon replicates the 1.6 kilobase telomere elongation and circadian restoration in larger cohorts, the mechanistic plausibility for healthspan benefits remains even if mortality effects are undetectable within research timelines. Rodent-to-human translation failure is common for lifespan interventions (antioxidants, growth hormone) but does not invalidate target engagement if the biomarker changes are reproducible.

What If Epithalon Interacts With Other Longevity Interventions?

Test combination protocols cautiously and monitor for synergistic risk. Combining Epithalon with mTOR inhibitors (rapamycin) or AMPK activators (metformin) could theoretically enhance autophagy and reduce senescent cell burden alongside telomere maintenance, but overlapping immune modulation or circadian disruption may also amplify adverse events. No controlled human data exist for Epithalon polypharmacy. Any multi-agent protocol is investigational and requires baseline and serial safety monitoring.

The Evidence-Based Truth About Epithalon Longevity Claims

Here's the honest answer: Epithalon is one of the few compounds with direct human evidence for somatic telomerase activation and telomere elongation. But the leap from 'telomeres lengthened' to 'lifespan extended' is enormous and unsupported by human data. The rodent studies are compelling: 12–16% median lifespan extension, reduced cancer incidence, preserved immune function. Those are meaningful effect sizes. But rodent aging is not human aging. Mice have telomeres 5–10 times longer than humans and vastly different tumor biology. The interventions that work best in mice. Caloric restriction, growth hormone suppression, mTOR inhibition. Show modest or null effects on human lifespan when tested rigorously.

What Epithalon does demonstrate in humans is reproducible biomarker modulation: telomeres lengthen, melatonin rhythm improves, oxidative stress markers decline. These are aging-associated changes moving in the right direction. Whether they translate to additional healthy years is unknown. The longest human study published is 12 months. That's a blink in the lifespan of a 70-year-old. No mortality data exist. No long-term adverse event profile exists.

The cancer risk is theoretical but not dismissable. Telomerase reactivation is the hallmark of cellular immortalization in malignancy. Short-term intermittent dosing hasn't triggered tumors in small studies, but 'hasn't yet' is not the same as 'won't.' If you're designing a research protocol around Epithalon, build in tumor surveillance and limit cumulative exposure until multi-year human safety data emerge. The mechanism is too proximal to oncogenesis to assume safety by default.

The bottom line: Epithalon engages biological targets that matter for aging. Chromosomal integrity, circadian function, oxidative defense. It does so with measurable, reproducible effects in controlled settings. That makes it a legitimate research tool for studying those mechanisms. It does not make it a validated longevity therapy. The gap between mechanistic plausibility and clinical proof is where most interventions fail. Epithalon hasn't crossed that gap yet.

Every peptide we produce at Real Peptides undergoes the same scrutiny: exact amino-acid sequencing, third-party purity verification, and sterile small-batch synthesis to guarantee research-grade consistency. We've built our protocols around the principle that mechanistic research requires flawless molecular fidelity. A single substitution or contamination event can invalidate months of work. Whether you're investigating Epithalon's telomerase kinetics, comparing it to mitochondrial-targeted peptides like MOTS-C, or designing multi-agent longevity studies, the compounds you source determine the validity of every conclusion you draw. That's not marketing. It's the reality of peptide research where purity isn't negotiable and every study's reproducibility depends on knowing exactly what molecule you injected.

References

Peer-reviewed sources on Epithalon indexed in PubMed, listed for research context. Real Peptides supplies Epithalon for laboratory research use only.

Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences, 2025. PMID 40141333. doi:10.3390/ijms26062691
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. PMID 40908429. doi:10.1007/s10522-025-10315-x
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports, 2025. PMID 40493162. doi:10.1007/s12015-025-10911-x
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 2022. PMID 35413689. doi:10.18632/aging.204007
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 2020. PMID 32019204. doi:10.3390/molecules25030609
Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of experimental biology and medicine, 2013. PMID 23658898. doi:10.1007/s10517-013-2029-0
Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of experimental biology and medicine, 2008. PMID 19110597. doi:10.1007/s10517-008-0121-7
Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. International journal of molecular medicine, 2003. PMID 12964022

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Epithalon upregulates transcription factors (c-Myc, Sp1) that bind the TERT gene promoter region, increasing telomerase reverse transcriptase mRNA and protein expression in somatic cells where the gene is otherwise silenced post-development. This transcriptional activation occurs without direct enzyme binding — the peptide modulates upstream regulatory pathways rather than functioning as a telomerase cofactor. In vitro studies show peak activity at 10–50 µM concentrations, with measurable telomerase activity increases of 33–42% in peripheral blood mononuclear cells within 10 days of administration.

Epithalon demonstrates active telomere elongation, not just attenuation of shortening. Human studies showed 1.6 kilobase mean increase in lymphocyte telomere length after two 10-day cycles separated by six months — this represents enzymatic addition of TTAGGG repeats to existing shortened telomeres, not merely preservation of current length. The magnitude of elongation depends on baseline telomere status, tissue type, and duration of exposure, but the mechanism is restorative rather than preventive.

Telomerase upregulation is present in 85–95% of human cancers and enables replicative immortality in transformed cells, making the theoretical oncogenic risk mechanistically valid. However, controlled studies using intermittent dosing protocols (10-day cycles every 6–12 months) showed no increase in circulating tumor markers or abnormal proliferation over 12-month observation periods. The distinction lies in duration and cellular context: short-term activation in non-transformed cells has not produced malignancy in published human trials, but continuous high-dose exposure remains unevaluated and represents unknown long-term risk.

Epithalon increases nocturnal pineal melatonin synthesis by 1.8–2.3-fold in aged animal models through upregulation of AANAT enzyme expression and activity. This partially explains anti-aging effects — melatonin independently reduces oxidative stress, stabilizes mitochondria, and modulates autophagy — but does not account for telomere elongation, which melatonin supplementation alone does not replicate. The mechanisms are complementary: circadian restoration and chromosomal maintenance operate through distinct pathways that converge on lifespan and healthspan outcomes observed in rodent studies.

Published human studies used 10-day administration cycles (subcutaneous injection, 10 mg total per cycle split across daily doses) repeated every 6–12 months. This intermittent protocol produced measurable telomere elongation and melatonin restoration while limiting cumulative telomerase exposure. Continuous dosing has not been evaluated in humans and carries theoretical oncogenic risk. Rodent longevity studies often used longer exposure durations, but interspecies translation of dose and timing remains uncertain — conservative approaches favor the validated human intermittent protocol until long-term safety data emerge.

Epithalon demonstrates telomerase activation primarily in proliferative cell populations — lymphocytes, fibroblasts, and epithelial cells show the strongest responses in published assays. Post-mitotic tissues (neurons, cardiomyocytes) express minimal telomerase even with Epithalon exposure, though the peptide still exerts neuroprotective and antioxidant effects through melatonin modulation and NF-κB pathway inhibition. Tissue-specific response correlates with baseline TERT promoter accessibility and proliferative capacity — cells retaining some mitotic potential show greater telomerase induction than terminally differentiated types.

Epithalon has direct controlled evidence for telomerase activity increases and telomere lengthening in human cells, whereas TA-65 (astragalus-derived cycloastragenol) shows minimal reproducible activity in independent assays and no consistent telomere elongation in published human trials. The mechanistic distinction is critical: Epithalon upregulates TERT gene expression through transcription factor modulation, while TA-65’s proposed mechanism remains poorly characterized and may reflect antioxidant effects rather than enzymatic telomerase activation. Evidence tier and reproducibility strongly favor Epithalon for telomere-focused research.

Essential biomarkers include telomere length (quantitative PCR or flow-FISH methods in peripheral blood lymphocytes), telomerase activity (TRAP assay in isolated cell populations), nocturnal melatonin levels (salivary or urinary 6-sulfatoxymelatonin), and tumor surveillance markers (CEA, AFP, PSA depending on demographic risk factors). Secondary markers — oxidative stress indices (malondialdehyde, 8-OHdG), inflammatory cytokines (TNF-α, IL-6), and immune function panels (lymphocyte proliferation assays) — provide mechanistic context. Monitoring intervals of 3–6 months capture dynamic changes while allowing detection of adverse trends before they become clinically significant.

No controlled human data exist for Epithalon combination protocols with other longevity drugs. Theoretical synergy exists — mTOR inhibition (rapamycin) or AMPK activation (metformin) could enhance autophagy and senescent cell clearance alongside Epithalon’s telomere maintenance — but overlapping immune modulation may amplify adverse events or create unpredictable interactions. Any multi-agent protocol is investigational and requires baseline safety monitoring, serial biomarker assessment, and conservative dose escalation. Monotherapy characterization should precede combination studies given the limited human safety profile for Epithalon at this stage.

Telomere elongation measured after Epithalon cycles persists for at least 6–12 months post-administration based on follow-up measurements in human studies, though gradual shortening resumes as normal mitotic activity continues without ongoing telomerase support. Melatonin rhythm improvements show durability of 30–60 days in rodent models before returning toward baseline, suggesting neuroendocrine effects require more frequent dosing or maintenance cycles than chromosomal changes. Effect durability likely varies by tissue type, baseline aging status, and concurrent lifestyle or pharmacological factors — no human studies extend beyond 12-month observation windows.

Epithalon demonstrates neuroprotective effects in preclinical models — reduced hippocampal neuronal loss, improved spatial memory, lower neuroinflammatory cytokine levels — but the mechanisms are primarily antioxidant and melatonin-mediated rather than telomere-dependent, since mature neurons are post-mitotic and lack significant telomerase activity. Research utility exists for studying circadian disruption in neurodegeneration (common in Alzheimer’s and Parkinson’s disease) or testing whether systemic telomerase activation in peripheral immune cells influences CNS inflammation. Direct neuronal telomere rescue is not a plausible mechanism given cell-type limitations.

Sample sizes remain small (typically fewer than 50 participants per study), observation periods are short (maximum 12 months in published trials), and no mortality or long-term healthspan data exist. Most human evidence comes from studies conducted in Russia with limited independent replication in other populations or research groups. Tumor surveillance periods are insufficient to detect slow-developing malignancies that might arise from chronic telomerase activation. Dosing protocols lack formal optimization — current regimens derive from early animal studies rather than human pharmacokinetic or dose-response trials. These gaps mean Epithalon remains a mechanistically promising but clinically unvalidated intervention.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA